CTO1681
CAR T-Cell/TCE Therapy-Related Inflammation (CRS/ICANS)
Key Facts
About CytoAgents
CytoAgents is pioneering a novel, steroid-sparing approach to modulate hyperactive immune responses that drive severe toxicities and limit the efficacy of transformative therapies. Its lead asset, CTO1681, is a prostaglandin/prostacyclin pathway inhibitor designed to safely dampen cytokine storms while preserving immune function, currently in Phase 1b/2a trials for CAR T-cell therapy-related inflammation. The company aims to expand into multiple inflammatory indications where viral or bacterial infections exacerbate disease, positioning CTO1681 as a potential foundational immunomodulator. Founded in 2016 and based in San Diego, CytoAgents is a private, pre-revenue company advancing its first-in-class oral therapy through clinical development.
View full company profileAbout CytoAgents
CytoAgents is pioneering a novel, steroid-sparing approach to modulate hyperactive immune responses that drive severe toxicities and limit the efficacy of transformative therapies. Its lead asset, CTO1681, is a prostaglandin/prostacyclin pathway inhibitor designed to safely dampen cytokine storms while preserving immune function, currently in Phase 1b/2a trials for CAR T-cell therapy-related inflammation. The company aims to expand into multiple inflammatory indications where viral or bacterial infections exacerbate disease, positioning CTO1681 as a potential foundational immunomodulator. Founded in 2016 and based in San Diego, CytoAgents is a private, pre-revenue company advancing its first-in-class oral therapy through clinical development.
View full company profileAbout CytoAgents
CytoAgents is pioneering a novel, steroid-sparing approach to modulate hyperactive immune responses that drive severe toxicities and limit the efficacy of transformative therapies. Its lead asset, CTO1681, is a prostaglandin/prostacyclin pathway inhibitor designed to safely dampen cytokine storms while preserving immune function, currently in Phase 1b/2a trials for CAR T-cell therapy-related inflammation. The company aims to expand into multiple inflammatory indications where viral or bacterial infections exacerbate disease, positioning CTO1681 as a potential foundational immunomodulator. Founded in 2016 and based in San Diego, CytoAgents is a private, pre-revenue company advancing its first-in-class oral therapy through clinical development.
View full company profile